Emerald Health Therapeutics’ Cannabis Sublingual Tablet Provides Consumers with Predictable Action and Advances Defined Dose™ Offering


Ryan Allway

April 13th, 2021

News


First-to-market rapidly-dissolving tablet offers controlled onset and offset; reflects Emerald’s focus on science-based innovation and expands products available under SYNC™ Wellness brand

 

VANCOUVER, BC, April 13, 2021 /CNW/ – Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH) (OTCQX: EMHTF) has launched its new product line, SYNC™ Tabs, an innovative, naturally-flavoured ingestible offering consumers a controlled 10 mg THC dose with predictable onset and offset. This product line expands its offering under its SYNC™ Wellness brand and is the second of Emerald’s Defined Dose™ products. The first provincial purchase orders have been received and, beginning April 13th, the tablets will be available to consumers at licensed cannabis retailers and online in BC, Manitoba, and Newfoundland, with Alberta to follow.

 

Emerald’s Cannabis 2.0 and 3.0 strategy focuses on leveraging science-based innovation to serve targeted consumer preferences. This differentiated new product line builds on Emerald’s commitment to offering consumers defined dosing and predictable actions that let them control their cannabis consumption experience. SYNC™ Tabs are designed in a familiar tablet form that enables convenient yet discreet cannabis use.

 

With 10 mg of THC, SYNC™ Tabs offer consumers the measured stringency of Emerald’s Defined Dose™ standard, dissolve under the tongue in about three minutes, and provide desired effects within 20 to 30 minutes. Offset is equally controlled, occurring within approximately 90 minutes of taking the tablet. This new product line follows the introduction of Emerald’s Nano Fast-Acting Spray product. Sublingual tablets add to the SYNC™ brand’s line-up of non-smoking forms of cannabis products, which also include CBD and THC cannabis oils.

 

Designed to serve customers’ use of cannabis for daily wellness routines, SYNC™ Tabs are sugar-free, gluten-free, vegan and come in two natural flavours, cherry and mint. Produced with 100-percent coconut-derived MCT oil, the products offer a sustainably-produced cannabis wellness option. Each pack contains 10 x 10 mg doses, offering 100 mg of THC in total.

 

“Our product development efforts are centered on providing consumers with distinctive cannabis products offering controlled, predictable actions – with greater precision of dosing and the onset and offset of effects,” said Riaz Bandali, President and CEO. “We have a talented product development team that is passionate about science and innovation. They are moving additional new product lines toward launches planned for the next few months and quarters, which we expect to start positively impacting our growth.”

 

About SYNC™

SYNC™ Wellness is dedicated to helping create balance in everyday life through innovative “smoke-free” cannabis products that are discreet and made with natural ingredients. Enjoy SYNC™ products any time of day with the confidence of precise and defined dosing. Focused on a holistic approach to cannabis consumption to fit your lifestyle, you will be able to incorporate SYNC™ into your everyday wellness routine. For more information about SYNC™ Tabs, visit www.emeraldhealth.ca/products/sync-wellness.

@syncwellness.ca

 

About Emerald Health Therapeutics
Emerald is committed to creating new consumer experiences with distinct recreational, medical and wellness-oriented cannabis products with an emphasis on innovation and product excellence.

 

Please visit www.emeraldhealth.ca for more information or contact:

 

Jenn Hepburn, Chief Financial Officer
(800) 757 3536 Ext. #5

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements.

 

We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties related to, among other things, changes of law and regulations; changes of government; failure to obtain regulatory approvals or permits; failure to obtain necessary financing; results of product development, production and sale activities; changes in prices and costs of inputs; demand for products; changes in business strategy; as well as the risk factors described in Emerald’s annual information form and other regulatory filings. The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management’s current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. Emerald undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.

 

SOURCE Emerald Health Therapeutics

For further information: Emerald Investor Relations, (800) 757 3536 Ext. #5, [email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading